VEGF和NSE在良恶性嗜铬细胞瘤组织中的表达及意义
|
摘要
目的探讨肿瘤标记物血管内皮生长因子(VEGF)和神经元特异性烯醇化酶(NSE)在良恶性嗜铬细胞瘤组织中的表达,分析其可能的临床价值及病理学意义,为临床鉴别良恶性嗜铬细胞瘤提供辅助依据。
方法本研究应用免疫组化(SP法)检测16例恶性嗜铬细胞瘤组织、18例良性嗜铬细胞瘤组织及17例正常肾上腺髓质组织中细胞因子VEGF和NSE表达情况,显微镜下判断组织切片的染色结果。
结果1、VEGF阳性表达率在正常肾上腺髓质、良性和恶性嗜铬细胞瘤中分别为17.64%、33.33%和81.25%,恶性嗜铬细胞瘤VEGF表达明显强于正常肾上腺髓质和良性嗜铬细胞瘤(P＜0.01)。良性肿瘤和正常肾上腺髓质的VEGF表达无显著性差异(P＞0.05)。恶性嗜铬细胞瘤强阳性率明显高于良性嗜铬细胞瘤(P=0.003,＜0.01)。2、NSE阳性表达率在三组中比例分别为11.76%、50.00%和87.50%,良、恶性嗜铬细胞瘤NSE表达差异有显著性意义(P＜0.05),良性嗜铬细胞瘤NSE的表达高于正常肾上腺髓质的NSE表达(P＜0.05)。恶性嗜铬细胞瘤强阳性率高于良性嗜铬细胞瘤(P=0.030,＜0.05)。3、VEGF和NSE共同阳性表达在良恶性嗜铬细胞瘤之间有显著性差异(P=0.004,＜0.01)。
结论1、VEGF在恶性嗜铬细胞瘤组织中的表达明显高于良性嗜铬细胞瘤。VEGF可能为鉴别良恶性嗜铬细胞瘤提供辅助生物学指标。2、NSE在恶性嗜铬细胞瘤组织中的表达高于良性嗜铬细胞瘤。NSE可能为鉴别良恶性嗜铬细胞瘤提供辅助生物学指标。3、临床上检测VEGF和NSE可能为鉴别良恶性嗜铬细胞瘤提供辅助依据,共同检测VEGF和NSE可能提高良恶性嗜铬细胞瘤鉴别的敏感性。
Objective:To study the expression and significance of tumor makers (VEGF and NSE)in benign and malignant pheochromocytoma.Analyze the possible clinical value and pathological significance.And providing assist basis to distinguish its benign and malignant.
Methods:The tissue of the tumor was embedded with the paraffin after operation with 18 cases of benign tumor,16 cases of malignant tumor and 17 cases of normal adrenal medulla.The intensity and area of the expression for VEGF and NSE was studied by immunohistochemical staining in different tissue.The results of the staining were judged under the microscope.
Results:1、The positive rate of staining for VEGF is 17.64%、33.33% and 81.25%in the section of normal,benign and malignant tissue, respectively.The positive rate for VEGF in malignant is significant higher than benign tissue(P＜0.01).The positive rate of staining for VEGF has no significant difference between benign and normal tissue (P＞0.05).The strong positive rate for VEGF in malignant is significant higher than benign tissue(P=0.003,＜0.01).2、The positive rate of staining for NSE is 11.76%、50.00%and 87.50%in the section of normal,benign and malignant tissue.The positive rate of staining for NSE has significant difference between benign and malignant pheochromocytoma(P＜0.05).And the expression in benign tissue is also higher than normal tissue(P＜0.05).The strong positive rate for VEGF in malignant is higher than benign tissue(P=0.030,＜0.05).3、The copositive rate of VEGF and NSE in malignant tissue is higher than benign tissue(P=0.004,＜0.01).
Conclusion:1、The expression of VEGF in malignant pheochromocytoma is significant higher than the benign tissue,and it may provide an assist biology index to distinguish the benign and malignant pheochromocytoma.2、The expression of NSE in malignant pheochromocytoma is higher than the benign tissue,and it may provide an assist biology index to distinguish the benign and malignant pheochromocytoma.3、Clinically,the detection of VEGF and NSE may offer assist basis to distinguish the benign and malignant pheochromocytoma.And the co-detection may elevate the sensitivity.
方法本研究应用免疫组化(SP法)检测16例恶性嗜铬细胞瘤组织、18例良性嗜铬细胞瘤组织及17例正常肾上腺髓质组织中细胞因子VEGF和NSE表达情况,显微镜下判断组织切片的染色结果。
结果1、VEGF阳性表达率在正常肾上腺髓质、良性和恶性嗜铬细胞瘤中分别为17.64%、33.33%和81.25%,恶性嗜铬细胞瘤VEGF表达明显强于正常肾上腺髓质和良性嗜铬细胞瘤(P＜0.01)。良性肿瘤和正常肾上腺髓质的VEGF表达无显著性差异(P＞0.05)。恶性嗜铬细胞瘤强阳性率明显高于良性嗜铬细胞瘤(P=0.003,＜0.01)。2、NSE阳性表达率在三组中比例分别为11.76%、50.00%和87.50%,良、恶性嗜铬细胞瘤NSE表达差异有显著性意义(P＜0.05),良性嗜铬细胞瘤NSE的表达高于正常肾上腺髓质的NSE表达(P＜0.05)。恶性嗜铬细胞瘤强阳性率高于良性嗜铬细胞瘤(P=0.030,＜0.05)。3、VEGF和NSE共同阳性表达在良恶性嗜铬细胞瘤之间有显著性差异(P=0.004,＜0.01)。
结论1、VEGF在恶性嗜铬细胞瘤组织中的表达明显高于良性嗜铬细胞瘤。VEGF可能为鉴别良恶性嗜铬细胞瘤提供辅助生物学指标。2、NSE在恶性嗜铬细胞瘤组织中的表达高于良性嗜铬细胞瘤。NSE可能为鉴别良恶性嗜铬细胞瘤提供辅助生物学指标。3、临床上检测VEGF和NSE可能为鉴别良恶性嗜铬细胞瘤提供辅助依据,共同检测VEGF和NSE可能提高良恶性嗜铬细胞瘤鉴别的敏感性。
Objective:To study the expression and significance of tumor makers (VEGF and NSE)in benign and malignant pheochromocytoma.Analyze the possible clinical value and pathological significance.And providing assist basis to distinguish its benign and malignant.
Methods:The tissue of the tumor was embedded with the paraffin after operation with 18 cases of benign tumor,16 cases of malignant tumor and 17 cases of normal adrenal medulla.The intensity and area of the expression for VEGF and NSE was studied by immunohistochemical staining in different tissue.The results of the staining were judged under the microscope.
Results:1、The positive rate of staining for VEGF is 17.64%、33.33% and 81.25%in the section of normal,benign and malignant tissue, respectively.The positive rate for VEGF in malignant is significant higher than benign tissue(P＜0.01).The positive rate of staining for VEGF has no significant difference between benign and normal tissue (P＞0.05).The strong positive rate for VEGF in malignant is significant higher than benign tissue(P=0.003,＜0.01).2、The positive rate of staining for NSE is 11.76%、50.00%and 87.50%in the section of normal,benign and malignant tissue.The positive rate of staining for NSE has significant difference between benign and malignant pheochromocytoma(P＜0.05).And the expression in benign tissue is also higher than normal tissue(P＜0.05).The strong positive rate for VEGF in malignant is higher than benign tissue(P=0.030,＜0.05).3、The copositive rate of VEGF and NSE in malignant tissue is higher than benign tissue(P=0.004,＜0.01).
Conclusion:1、The expression of VEGF in malignant pheochromocytoma is significant higher than the benign tissue,and it may provide an assist biology index to distinguish the benign and malignant pheochromocytoma.2、The expression of NSE in malignant pheochromocytoma is higher than the benign tissue,and it may provide an assist biology index to distinguish the benign and malignant pheochromocytoma.3、Clinically,the detection of VEGF and NSE may offer assist basis to distinguish the benign and malignant pheochromocytoma.And the co-detection may elevate the sensitivity.
引文
[1]Ferrara N,Davis-Smyth TD.The biology of vascular endothelial growth factor.EndocrRev,1997,18(1):4-25.
[2]Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel heprin-binding growth factor specific for vascular endothelial cell.Biochem Biophys Res Commun,1989,161(2):851-858.
[3]Leung DW,Cachlanes G,Kuang WJ,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science,1989,246:1306-1309.
[4]Takekoshi K,Isobe K.Expression of vascular endothelial growth factor (VEGF)and its cognate receptors in human pheochromocytomas.Life Sci,2004,74(7):863-871.
[5]Klesse LJ,Meyers KA,Marshall CJ,et al.Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC 12cells.Oncogene,1999,18(12):2055-2068.
[6]Nakatani A,Yamada M,Asada A,et al.Comparison of survival promoting effects of brain-derived neurotrophic factor and neurotrophin-3 on PC 12h cells stably expressing TrkB receptor.J Biochem(Tokyo),1998,123(4):707-714.
[7]Thompson LD.Pheochromocytoma of the Adrenal gland Scaled Score(PASS)to separate benign from malignant neoplasms:a clinicopathologic and immunophenotypic study of 100 cases.Am J Surg Pathol,2002,26(5):551-566.
[8]Shimizu M,Raitoh Y,Ltoh H,et al.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues.Hum Pathol,1990,21(6):607-612.
[9]邵鹏飞,钱立新.恶性嗜铬细胞瘤诊断进展.国外医学泌尿系统分册,2004,24(1):51-53.
[10]Jaquet K,Krause KT,Khodai M.Erythropoietin and VEGF exhibit equal angiogenic potential.Microvasc Res,2002,64(2):326-333.
[11]Harold FD.Vascular permeability factor/vascular endothelial growth factor:a critical cytokine in tumor andiogenesis and a potential target for diagnosis and therapy.Journal of Clinical Oncology,2002,20(21):4368-4380.
[12]Helen ET,Adrian LH,Shlomo M,et al.Angiogenesis in endocrine tumor.Endocrine,2003,24(5):600-632.
[13] Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clinical, 2004, 130(9): 514-520.
[14] Liotta LA, Stracke ML. Tumor invasion and metastasis: biochemical mechanisms. Cancer Treat Res, 1988, 40: 223-238.
[15] Laughner E, Taghavi P, Chiles K, et al. Her2 (neu) signaling increases the rate of hypoxia-inducible-factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mot Cell Biol, 2001, 21 (12) : 3995-4004.
[16] Favier J, Plouin PF, Corvol P, et al. Angiogenesis and vascular architecture in pheochromocytomas: distinctive trait in malignant tumor. Am J Pathol, 2002, 161 (4) : 1235-1246.
[17] Zielke A, Middeke M, Hoffmann S, et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132 (6) : 1056-1063.
[18] Tor Ingebrigtsen, Bertil Romner. Biochemical serum markers of traumatic brain injury. J Trauma, 2002, 52 (4) : 798-808.
[19] Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrin cells. Annu Rev Neurosci, 1987, 10: 269-295.
[20] Oliva D, Cali L, Feo S, et al. Complete structure of the human gene encoding neuron-specific enolase Genomics, 1991, 10 (1) : 157-165
[21] Johnsson P. Markers of cerebral ischemia after cardiac surgery. J Cardiothorac Vasc Anesth, 1996, 10 (1) : 120-126.
[22] Nygaard, Langbakk B, Romner B. Neuro-specific enolase concentrations in serum and cerebrospinal fluid in patients with previous history of neurological disorder. Scand J Clin Lab Invest, 1998, 58: 183-186.
[23] Raabe A, Grolms C, Keller M, et al. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochirurgica, 1998, 140 (8) : 787-792.
[24] Moreno AM, Castilla-Guerra L, Martinez-Torres MC, et al. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides, 1999, 33 (2) : 159-163.
[25]Maryniak RK,Szczaluba K,Ignatowska-Switalska M,et al.Immunomorphological studies and cytometric DNA ploidy in diagnostics of pheochromocytoma.Pol J Pathol,2000,51(2):83-86.
[26]Grouzmann E,Gicquel C,Plouin PF,et al.Neuropeptide Y and neuron-specific enolas levels in benign and malignant pheochromocytomas.Cancer,1990,66(8):1833-1835.
[27]Ronald A.Delellis,主编.江昌新,主译.内分泌器官肿瘤病理学和遗传学/世界卫生组织肿瘤分类及诊断标准系列,第一版.人民卫生出版社,2006,164-165.
[28]Pinson P,Joos G,Watripont P,et al.Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small cell lung cancer.Respiration,1997,64:102-107.
[29]Pujol JL,Boher JM,Grenier J,et al.Neuron-specific enolase(NSE)in the surveillance of small cell lung cancer:an evaluation of the prognostic information using Markov's model.Rev Mal Respir,1998,15(4):519-525.
[30]Kamiya N,Akakura K,Suzuki H,et al.Pretreatment Serum Level of Neuron Specific Enolase(NSE)as a Prognostic Factor in Metastatic Prostate Cancer Patients Treated with Endocrine Therapy.European Urology,2003,44(3):309-314.
[31]康福霞,杨浩,吴玉梅等.NSE-ELISA技术在良恶性嗜铬细胞瘤鉴别诊断中的应用.中国综合临床,2003,19(2):175-176.
[32]钱立新,邵鹏飞,吴宏飞等.肿瘤标记物在恶性嗜铬细胞瘤组织中的表达及意义.中华实验外科杂志,2005,22(12):1549-1551.
[1] Folkman J, Klagsbum M. Angiogenic factor. Science, 1987,235:442-447.
[2] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86 (3) : 353-364.
[3] Bategay EJ. Angiogenesis: mechanism insights, neovascular diseases, and therapeutic prospects. J Mot Med, 1995, 73 (7) : 333-346.
[4] BouckN, Stellmach V, Hsu SC, et al. How tumors become angiogenic. Adc Cancer Res, 1996, 69: 135-174.
[5] Ferrara N, Davis-Smyth TD. The biology of vascular endothelial growth factor. Endocrine Reviews, 1997, 18 (1) : 4-25.
[6] Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heprin -binding growth factor specific for vascular endothelial cell. Biochem Biophys Res Commun, 1989, 161 (2) : 851-8.
[7] Leung DW, Cachlanes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246 (4935) : 1306-9.
[8] Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219 (4587) : 983-985.
[9] Abu-Ghazaleh R, Kabir J, Jia H, et al. Src mediates stimulation by vascular endothelial growth factor of the phospharylation of focal adhesion kinase at tyrosine 861 and migration and anti-apoptsis in endothelial cells. Biochem J, 2001, 360 (1) : 55-264.
[10] Bates DO, Heald RI, Carry FE, et al.VEGF increases rana vascular permeability and compliance by different signaling pathways. J Physiol, 2001, P53 (pi11) : 263-265.
[11] Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and Von Willebrand factor release in human endothelial cells. Am J Pathol, 1991, 138: 213-221.
[12] Pepper MS, Ferrara N, Orci L, et al .Vascular endothelial growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophs Res Commun, 1991, 181 (2) : 902-906.
[13] Unemori EN, Ferrara N, Bauer EA, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physio, 1992, 153 (3) : 557-62.
[14] Mandriota S, MontesanoR, OricL, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem, 1995, 270 (17) : 9709-9716.
[15] Yoshida A, Anand B, Zeter B, et al. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.Growth Factors, 1996, 13 (1) : 57-64.
[16] Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med, 1990, 172 (6) : 1535-1545.
[17] Wilting J, Christ B, Bokeloh M, et al. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Tiss Res, 1993, 274 (1) : 163-172.
[18] Nicosia R, Nicosia S, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulinlike growth factor-1 promote rat aoric angiogenesis in vitro. Am J Pathol, 1994, 145 (5) : 1023-1029.
[19] Phillips GD, Stone AM, Jones BD, et al .Vascular endothelial growth factor (rhVEGF165)stimulates direct angiogenesis in the rabbit cornea. In Vivo, 1995, 8 (6) : 961-965.
[20] Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest, 1993, 69 (5) : 508-517.
[21] Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992, 267 (16) : 10931 -10934.
[22] Takeshita S, Rossow ST, Kearney M, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol, 1995, 147 (6) : 1649-1660.
[23] Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophs Acta, 1989, 948 (3) : 305-326.
[24] Keck PJ, Hauser SD, Krivi G, et al . Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 1989, 246 (4935) : 1309-1312.
[25] Dvorak HF. Tumors: wounds that do not heal. Similarity between tumor stroma generation and wound healing. N Engl J Med, 1986, 315: 1650-1658.
[26] Folkman J. The role of angiogenesis in tumor growth. Cancer Biol, 1992, 3 (2) : 65-71.
[27] Sunderkotter C, GoebelerM, Schulze-Osthoff k, et al. Macrophage-derived angiogenesis factors. Pharmacol Ther, 1991, 51 (2) : 195-216.
[28] Mattern J, Koomagi R, Volm M, et al. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma.Br J Cancer, 1996, 73 (7): 931-4.
[29] Maeda K, OgawaY, Takatsuka S, et al. Prognosic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 1996, 77 (5): 858-863.
[30] Brown LF, Berse B, Jackman RW, et al .Increased expression of vascular permeability factor(vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol, 1993, 143 (5) : 1255-1262.
[31] Brown LF, Berse B, Jackman RW, et al .Expression of vascular permeability factor (Vascular endothelial growth factor) and its receptor in breast cancer.. Human Pathol, 1995, 26 (1) : 86-91.
[32] Olson TA, Mohanraj D, Carson LF, et al .Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res, 1994, 54(1): 276-280.
[33] Guidi AJ, Abu-Jawden G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst, 1995, 87: 12137-12145.
[34] Hashimoto M, OhsawaM, Ohnishi A, et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest, 1995, 73 (6) : 859-63.
[35] Philips HS, Armanini M, Stavrou D, et al. Intense focal expression of vascular permeability factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol, 1993, 2: 913-919.
[36] Dvorak HF, SioussatTM, Brown LF, et al. Distribution of VEGF in tumors: concentration in tumor blood vessels. J Exp Med, 1991, 174 (5) : 1275-1278.
[37] Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature, 1992, 359: 845-848.
[38] Nakagawa M, Emoto A, Hanada T, et al. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor in renal cell carcinoma. Br J Urol, 1997, 79 (5) : 681-687.
[39] Toi M, Hoshima S, Takayanagi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Cancer Science, 1994, 85 (10) : 1045-1049.
[40] Maeda K, Chung YS, Takatsuka S, et al. Tumor angiogenesis and tumor cell proliferation as prognostic in dicators in gastric carcinoma. Br J Cancer, 1995, 72 (2) :. 319-323.
[41] Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res, 2000, 6 (3) : 1161-1168.
[42] Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 1993, 362 (1) : 841-844.
[43] Borgstrom P, Hillan KJ, Sriramao P, et al. Complete in hibition of angiogenesis and growth of micro tumors by anti-VEGF neutralizing antibody from intravital microscopy. Cancer Res, 1996, 56 (17) : 4032-4039.
[44] Shweiki'D, NeemanM, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci, 1995, 92 (3) : 768-772.
[45] Soumitro Pal, Kaustubh Datta, Debabrata Mukhopadhyay.Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma。 Cancer Research, 2001, 61 (18): 6952-6957.
[46] Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. Cancer Research, 2003, 63 (18): 5978-5991.
[47] Takekoshi K, Isobe K. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci, 2004, 74 (7): 863-871.
[48] FavierJ, Plouin PF, Corvol P, et al. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol, 2002, 161(4): 1235-1246.
[49] Zielke A, Middeke M, Hoffmann S, et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132(6): 1056-1063.
[50] Melnyk O, Zimmerman M, Kim KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol, 1999, 161(3): 960-963.
[2]Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel heprin-binding growth factor specific for vascular endothelial cell.Biochem Biophys Res Commun,1989,161(2):851-858.
[3]Leung DW,Cachlanes G,Kuang WJ,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science,1989,246:1306-1309.
[4]Takekoshi K,Isobe K.Expression of vascular endothelial growth factor (VEGF)and its cognate receptors in human pheochromocytomas.Life Sci,2004,74(7):863-871.
[5]Klesse LJ,Meyers KA,Marshall CJ,et al.Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC 12cells.Oncogene,1999,18(12):2055-2068.
[6]Nakatani A,Yamada M,Asada A,et al.Comparison of survival promoting effects of brain-derived neurotrophic factor and neurotrophin-3 on PC 12h cells stably expressing TrkB receptor.J Biochem(Tokyo),1998,123(4):707-714.
[7]Thompson LD.Pheochromocytoma of the Adrenal gland Scaled Score(PASS)to separate benign from malignant neoplasms:a clinicopathologic and immunophenotypic study of 100 cases.Am J Surg Pathol,2002,26(5):551-566.
[8]Shimizu M,Raitoh Y,Ltoh H,et al.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues.Hum Pathol,1990,21(6):607-612.
[9]邵鹏飞,钱立新.恶性嗜铬细胞瘤诊断进展.国外医学泌尿系统分册,2004,24(1):51-53.
[10]Jaquet K,Krause KT,Khodai M.Erythropoietin and VEGF exhibit equal angiogenic potential.Microvasc Res,2002,64(2):326-333.
[11]Harold FD.Vascular permeability factor/vascular endothelial growth factor:a critical cytokine in tumor andiogenesis and a potential target for diagnosis and therapy.Journal of Clinical Oncology,2002,20(21):4368-4380.
[12]Helen ET,Adrian LH,Shlomo M,et al.Angiogenesis in endocrine tumor.Endocrine,2003,24(5):600-632.
[13] Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clinical, 2004, 130(9): 514-520.
[14] Liotta LA, Stracke ML. Tumor invasion and metastasis: biochemical mechanisms. Cancer Treat Res, 1988, 40: 223-238.
[15] Laughner E, Taghavi P, Chiles K, et al. Her2 (neu) signaling increases the rate of hypoxia-inducible-factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mot Cell Biol, 2001, 21 (12) : 3995-4004.
[16] Favier J, Plouin PF, Corvol P, et al. Angiogenesis and vascular architecture in pheochromocytomas: distinctive trait in malignant tumor. Am J Pathol, 2002, 161 (4) : 1235-1246.
[17] Zielke A, Middeke M, Hoffmann S, et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132 (6) : 1056-1063.
[18] Tor Ingebrigtsen, Bertil Romner. Biochemical serum markers of traumatic brain injury. J Trauma, 2002, 52 (4) : 798-808.
[19] Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrin cells. Annu Rev Neurosci, 1987, 10: 269-295.
[20] Oliva D, Cali L, Feo S, et al. Complete structure of the human gene encoding neuron-specific enolase Genomics, 1991, 10 (1) : 157-165
[21] Johnsson P. Markers of cerebral ischemia after cardiac surgery. J Cardiothorac Vasc Anesth, 1996, 10 (1) : 120-126.
[22] Nygaard, Langbakk B, Romner B. Neuro-specific enolase concentrations in serum and cerebrospinal fluid in patients with previous history of neurological disorder. Scand J Clin Lab Invest, 1998, 58: 183-186.
[23] Raabe A, Grolms C, Keller M, et al. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochirurgica, 1998, 140 (8) : 787-792.
[24] Moreno AM, Castilla-Guerra L, Martinez-Torres MC, et al. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides, 1999, 33 (2) : 159-163.
[25]Maryniak RK,Szczaluba K,Ignatowska-Switalska M,et al.Immunomorphological studies and cytometric DNA ploidy in diagnostics of pheochromocytoma.Pol J Pathol,2000,51(2):83-86.
[26]Grouzmann E,Gicquel C,Plouin PF,et al.Neuropeptide Y and neuron-specific enolas levels in benign and malignant pheochromocytomas.Cancer,1990,66(8):1833-1835.
[27]Ronald A.Delellis,主编.江昌新,主译.内分泌器官肿瘤病理学和遗传学/世界卫生组织肿瘤分类及诊断标准系列,第一版.人民卫生出版社,2006,164-165.
[28]Pinson P,Joos G,Watripont P,et al.Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small cell lung cancer.Respiration,1997,64:102-107.
[29]Pujol JL,Boher JM,Grenier J,et al.Neuron-specific enolase(NSE)in the surveillance of small cell lung cancer:an evaluation of the prognostic information using Markov's model.Rev Mal Respir,1998,15(4):519-525.
[30]Kamiya N,Akakura K,Suzuki H,et al.Pretreatment Serum Level of Neuron Specific Enolase(NSE)as a Prognostic Factor in Metastatic Prostate Cancer Patients Treated with Endocrine Therapy.European Urology,2003,44(3):309-314.
[31]康福霞,杨浩,吴玉梅等.NSE-ELISA技术在良恶性嗜铬细胞瘤鉴别诊断中的应用.中国综合临床,2003,19(2):175-176.
[32]钱立新,邵鹏飞,吴宏飞等.肿瘤标记物在恶性嗜铬细胞瘤组织中的表达及意义.中华实验外科杂志,2005,22(12):1549-1551.
[1] Folkman J, Klagsbum M. Angiogenic factor. Science, 1987,235:442-447.
[2] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86 (3) : 353-364.
[3] Bategay EJ. Angiogenesis: mechanism insights, neovascular diseases, and therapeutic prospects. J Mot Med, 1995, 73 (7) : 333-346.
[4] BouckN, Stellmach V, Hsu SC, et al. How tumors become angiogenic. Adc Cancer Res, 1996, 69: 135-174.
[5] Ferrara N, Davis-Smyth TD. The biology of vascular endothelial growth factor. Endocrine Reviews, 1997, 18 (1) : 4-25.
[6] Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heprin -binding growth factor specific for vascular endothelial cell. Biochem Biophys Res Commun, 1989, 161 (2) : 851-8.
[7] Leung DW, Cachlanes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246 (4935) : 1306-9.
[8] Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219 (4587) : 983-985.
[9] Abu-Ghazaleh R, Kabir J, Jia H, et al. Src mediates stimulation by vascular endothelial growth factor of the phospharylation of focal adhesion kinase at tyrosine 861 and migration and anti-apoptsis in endothelial cells. Biochem J, 2001, 360 (1) : 55-264.
[10] Bates DO, Heald RI, Carry FE, et al.VEGF increases rana vascular permeability and compliance by different signaling pathways. J Physiol, 2001, P53 (pi11) : 263-265.
[11] Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and Von Willebrand factor release in human endothelial cells. Am J Pathol, 1991, 138: 213-221.
[12] Pepper MS, Ferrara N, Orci L, et al .Vascular endothelial growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophs Res Commun, 1991, 181 (2) : 902-906.
[13] Unemori EN, Ferrara N, Bauer EA, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physio, 1992, 153 (3) : 557-62.
[14] Mandriota S, MontesanoR, OricL, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem, 1995, 270 (17) : 9709-9716.
[15] Yoshida A, Anand B, Zeter B, et al. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.Growth Factors, 1996, 13 (1) : 57-64.
[16] Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med, 1990, 172 (6) : 1535-1545.
[17] Wilting J, Christ B, Bokeloh M, et al. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Tiss Res, 1993, 274 (1) : 163-172.
[18] Nicosia R, Nicosia S, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulinlike growth factor-1 promote rat aoric angiogenesis in vitro. Am J Pathol, 1994, 145 (5) : 1023-1029.
[19] Phillips GD, Stone AM, Jones BD, et al .Vascular endothelial growth factor (rhVEGF165)stimulates direct angiogenesis in the rabbit cornea. In Vivo, 1995, 8 (6) : 961-965.
[20] Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest, 1993, 69 (5) : 508-517.
[21] Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992, 267 (16) : 10931 -10934.
[22] Takeshita S, Rossow ST, Kearney M, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol, 1995, 147 (6) : 1649-1660.
[23] Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophs Acta, 1989, 948 (3) : 305-326.
[24] Keck PJ, Hauser SD, Krivi G, et al . Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 1989, 246 (4935) : 1309-1312.
[25] Dvorak HF. Tumors: wounds that do not heal. Similarity between tumor stroma generation and wound healing. N Engl J Med, 1986, 315: 1650-1658.
[26] Folkman J. The role of angiogenesis in tumor growth. Cancer Biol, 1992, 3 (2) : 65-71.
[27] Sunderkotter C, GoebelerM, Schulze-Osthoff k, et al. Macrophage-derived angiogenesis factors. Pharmacol Ther, 1991, 51 (2) : 195-216.
[28] Mattern J, Koomagi R, Volm M, et al. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma.Br J Cancer, 1996, 73 (7): 931-4.
[29] Maeda K, OgawaY, Takatsuka S, et al. Prognosic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 1996, 77 (5): 858-863.
[30] Brown LF, Berse B, Jackman RW, et al .Increased expression of vascular permeability factor(vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol, 1993, 143 (5) : 1255-1262.
[31] Brown LF, Berse B, Jackman RW, et al .Expression of vascular permeability factor (Vascular endothelial growth factor) and its receptor in breast cancer.. Human Pathol, 1995, 26 (1) : 86-91.
[32] Olson TA, Mohanraj D, Carson LF, et al .Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res, 1994, 54(1): 276-280.
[33] Guidi AJ, Abu-Jawden G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst, 1995, 87: 12137-12145.
[34] Hashimoto M, OhsawaM, Ohnishi A, et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest, 1995, 73 (6) : 859-63.
[35] Philips HS, Armanini M, Stavrou D, et al. Intense focal expression of vascular permeability factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol, 1993, 2: 913-919.
[36] Dvorak HF, SioussatTM, Brown LF, et al. Distribution of VEGF in tumors: concentration in tumor blood vessels. J Exp Med, 1991, 174 (5) : 1275-1278.
[37] Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature, 1992, 359: 845-848.
[38] Nakagawa M, Emoto A, Hanada T, et al. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor in renal cell carcinoma. Br J Urol, 1997, 79 (5) : 681-687.
[39] Toi M, Hoshima S, Takayanagi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Cancer Science, 1994, 85 (10) : 1045-1049.
[40] Maeda K, Chung YS, Takatsuka S, et al. Tumor angiogenesis and tumor cell proliferation as prognostic in dicators in gastric carcinoma. Br J Cancer, 1995, 72 (2) :. 319-323.
[41] Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res, 2000, 6 (3) : 1161-1168.
[42] Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 1993, 362 (1) : 841-844.
[43] Borgstrom P, Hillan KJ, Sriramao P, et al. Complete in hibition of angiogenesis and growth of micro tumors by anti-VEGF neutralizing antibody from intravital microscopy. Cancer Res, 1996, 56 (17) : 4032-4039.
[44] Shweiki'D, NeemanM, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci, 1995, 92 (3) : 768-772.
[45] Soumitro Pal, Kaustubh Datta, Debabrata Mukhopadhyay.Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma。 Cancer Research, 2001, 61 (18): 6952-6957.
[46] Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. Cancer Research, 2003, 63 (18): 5978-5991.
[47] Takekoshi K, Isobe K. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci, 2004, 74 (7): 863-871.
[48] FavierJ, Plouin PF, Corvol P, et al. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol, 2002, 161(4): 1235-1246.
[49] Zielke A, Middeke M, Hoffmann S, et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132(6): 1056-1063.
[50] Melnyk O, Zimmerman M, Kim KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol, 1999, 161(3): 960-963.